Glytherix

Glytherix

GlyTherix Ltd is an Australian radiotherapy company specializing in therapeutics for solid tumors, expressing Glypican-1 (GPC-1). GPC-1 occurs in many solid tumors such as prostate, bladder, pancreatic, glioblastoma, esophageal, lung and ovarian cancers. It is not detectable in healthy tissue.

The company has a strong intellectual property position covering both its anti-GPC-1 antibody and the antigen itself, GPC-1. This provides robust and long-term protection for the commercialization of important new treatments to people with little hope. GlyTherix has now completed a ‘First-in-Human’ trial of 12 patients using Miltuximab® with no drug-related adverse events observed. GlyTherix is interested in partnerships or collaborations with larger pharmaceutical partners.

Learn more about GlyTherix